the failed osteoporosis drug that became a bodybuilding staple
1995-1996 (chemistry published; receptor cloned) — broader arc 1977-1999
Merck's chemists built a drug that perfectly fit a lock three years before anyone on Earth knew what the key looked like.
The story of MK-677 begins not in a corporate lab but at Tulane University in 1977, where endocrinologist Cyril Bowers and chemist Frank Momany stumbled onto something strange: synthetic peptides that looked chemically like opioids but triggered a sudden burst of growth hormone with none of the opioid effects. Over the next seven years they honed the discovery into GHRP-6 (1984), the first peptide purpose-built to make the pituitary gland dump growth hormone on command. The catch was that nobody knew how it worked — what receptor it grabbed, or what natural hormone normally pulled the same trigger. It was, in the truest sense, a key with no known lock.
In the early 1990s, Merck's medicinal chemistry group in Rahway, New Jersey, picked up the thread with a very practical goal: turn Bowers' injectable peptide into a pill you could swallow. Working backward from GHRP-6 in a classic feat of 'reverse pharmacology,' Patchett, Smith, and colleagues engineered a non-peptide spiroindoline compound, published in 1995 (PNAS) as MK-0677 — orally active, once-daily, and just as potent in animals. Then came the twist that still turns heads: in 1996, Merck scientists (Howard et al., Science) used MK-677 itself as a molecular probe to clone the receptor it was hitting — an 'orphan' receptor with no known natural partner. Merck owned a finished, patented drug docked onto that receptor for three full years before anyone identified the body's own signal for it: ghrelin, the stomach's now-famous 'hunger hormone,' finally isolated in 1999 by Kojima and colleagues in Japan (Nature), who built directly on the receptor Merck's program had already mapped.
On paper, MK-677 looked like the oral anti-frailty pill an aging world was waiting for. Human trials led largely by endocrinologist Michael Thorner at the University of Virginia showed it reliably restored youthful growth-hormone and IGF-1 levels in elderly subjects, deepened sleep, built lean mass, and even reversed diet-induced muscle wasting in healthy volunteers (JCEM, 1997–1998). But the promise curdled: the extra muscle came without the payoff that mattered — no better grip strength, no better mobility — a verdict later nailed down by a 2008 Annals of Internal Medicine trial (Nass, Thorner et al.), and Merck stepped back from its anti-frailty ambitions around 1999. The door was shut for good more than a decade later, when a hip-fracture trial (Adunsky et al., 2011) flagged more congestive-heart-failure events in treated patients than placebo, plus worsened insulin resistance and fluid retention. MK-677 never had an NDA filed, and never won FDA approval.
That should have been the end of the story. Instead, the very thing that made MK-677 attractive to Merck — a pill, no needles, no reconstitution, no refrigerated vials — made it perfect for the gray market. Through the 2000s and 2010s it drifted onto bodybuilding and biohacking forums under the name ibutamoren, sold as a 'research chemical' rather than a drug: not scheduled by the DEA, banned by WADA for tested athletes, but with essentially no barrier to a private buyer ordering it online.
The jaw-dropping core of this story holds up beautifully — three separate peer-reviewed papers confirm that Merck had a finished drug sitting on its receptor for three years before anyone found the body's matching hormone. What's embellished is the tidy timeline of Merck's exit: the famous hip-fracture heart-failure trial wasn't published until 2011, roughly a decade after the company had already stepped back, so it couldn't have been the single cause of a clean late-1990s shutdown.
Ibutamoren remains, formally, an unapproved investigational drug — no country has ever licensed it for human use. In the US it's legal to possess (it isn't DEA-scheduled) but banned by WADA/USADA for any tested athlete, and it is not a legal dietary-supplement ingredient despite being marketed like one; it circulates almost entirely through unregulated vendors with no purity guarantees. The more interesting new chapter is that the same molecule has been revived as <b>LUM-201</b> by <b>Lumos Pharma</b>, now in Phase 2/3 trials for pediatric growth-hormone deficiency — the exact drug Merck walked away from a quarter-century ago is working its way back toward the FDA approval it never got, this time for a far narrower and more defensible patient group than the one that sank it in the 1990s.
